Use of antineoplastic agents in patients with cancer who have HIV/AIDS

Michelle A. Rudek; Charles Flexner; Richard F. Ambinder

doi:10.1016/S1470-2045(11)70056-0

Use of antineoplastic agents in patients with cancer who have HIV/AIDS

Michelle A. Rudek
, Charles Flexner
, Richard F. Ambinder

School of Medicine

Research output: Contribution to journal › Review article › peer-review

84 Scopus citations

Abstract

Highly active antiretroviral therapy (HAART) has substantially reduced morbidity and mortality of AIDS-related complications in patients with HIV; however, the prevalence of AIDS-defining cancers and non-AIDS-defining cancers has increased. In this Review we discuss the management of HAART pharmacotherapy in relation to cytotoxic chemotherapy or targeted antineoplastic agents. We will review potential pharmacological interactions between antiretroviral and antineoplastic therapies and consider how to combine antiretroviral and antineoplastic agents in patients with HIV who are receiving HAART therapy.

Original language	English (US)
Pages (from-to)	905-912
Number of pages	8
Journal	The Lancet Oncology
Volume	12
Issue number	9
DOIs	https://doi.org/10.1016/S1470-2045(11)70056-0
State	Published - Sep 2011

ASJC Scopus subject areas

Oncology

Access to Document

10.1016/S1470-2045(11)70056-0

Cite this

@article{25466753302d4959a84e1e425d8d7c93,

title = "Use of antineoplastic agents in patients with cancer who have HIV/AIDS",

abstract = "Highly active antiretroviral therapy (HAART) has substantially reduced morbidity and mortality of AIDS-related complications in patients with HIV; however, the prevalence of AIDS-defining cancers and non-AIDS-defining cancers has increased. In this Review we discuss the management of HAART pharmacotherapy in relation to cytotoxic chemotherapy or targeted antineoplastic agents. We will review potential pharmacological interactions between antiretroviral and antineoplastic therapies and consider how to combine antiretroviral and antineoplastic agents in patients with HIV who are receiving HAART therapy.",

author = "Rudek, \{Michelle A.\} and Charles Flexner and Ambinder, \{Richard F.\}",

note = "Funding Information: All authors are partly supported by a National Cancer Institute grant ( U01 CA 121947 ) to the AIDS Malignancy Consortium, which has facilitated interactions related to this Review. CF is partly supported by National Institute of Allergy and Infectious Disease grants ( U01 AI 069465 and AI 068636 ). Funding Information: CF has received grant support from GlaxoSmithKline; has served on scientific advisory boards for Bristol-Myers Squibb, GlaxoSmithKline, Merck Pharmaceuticals, Tibotec Pharmaceuticals, Boehringer-Ingelheim, Virostatics, and Inhibitex; and has received honoraria from Abbott Laboratories. MAR has received payment for consultancy from Concordia Pharmaceuticals. RFA declared no conflicts of interest. ",

year = "2011",

month = sep,

doi = "10.1016/S1470-2045(11)70056-0",

language = "English (US)",

volume = "12",

pages = "905--912",

journal = "The Lancet Oncology",

issn = "1470-2045",

publisher = "Elsevier Ltd",

number = "9",

}

TY - JOUR

T1 - Use of antineoplastic agents in patients with cancer who have HIV/AIDS

AU - Rudek, Michelle A.

AU - Flexner, Charles

AU - Ambinder, Richard F.

N1 - Funding Information: All authors are partly supported by a National Cancer Institute grant ( U01 CA 121947 ) to the AIDS Malignancy Consortium, which has facilitated interactions related to this Review. CF is partly supported by National Institute of Allergy and Infectious Disease grants ( U01 AI 069465 and AI 068636 ). Funding Information: CF has received grant support from GlaxoSmithKline; has served on scientific advisory boards for Bristol-Myers Squibb, GlaxoSmithKline, Merck Pharmaceuticals, Tibotec Pharmaceuticals, Boehringer-Ingelheim, Virostatics, and Inhibitex; and has received honoraria from Abbott Laboratories. MAR has received payment for consultancy from Concordia Pharmaceuticals. RFA declared no conflicts of interest.

PY - 2011/9

Y1 - 2011/9

N2 - Highly active antiretroviral therapy (HAART) has substantially reduced morbidity and mortality of AIDS-related complications in patients with HIV; however, the prevalence of AIDS-defining cancers and non-AIDS-defining cancers has increased. In this Review we discuss the management of HAART pharmacotherapy in relation to cytotoxic chemotherapy or targeted antineoplastic agents. We will review potential pharmacological interactions between antiretroviral and antineoplastic therapies and consider how to combine antiretroviral and antineoplastic agents in patients with HIV who are receiving HAART therapy.

AB - Highly active antiretroviral therapy (HAART) has substantially reduced morbidity and mortality of AIDS-related complications in patients with HIV; however, the prevalence of AIDS-defining cancers and non-AIDS-defining cancers has increased. In this Review we discuss the management of HAART pharmacotherapy in relation to cytotoxic chemotherapy or targeted antineoplastic agents. We will review potential pharmacological interactions between antiretroviral and antineoplastic therapies and consider how to combine antiretroviral and antineoplastic agents in patients with HIV who are receiving HAART therapy.

UR - https://www.scopus.com/pages/publications/80052369811

UR - https://www.scopus.com/pages/publications/80052369811#tab=citedBy

U2 - 10.1016/S1470-2045(11)70056-0

DO - 10.1016/S1470-2045(11)70056-0

M3 - Review article

C2 - 21570912

AN - SCOPUS:80052369811

SN - 1470-2045

VL - 12

SP - 905

EP - 912

JO - The Lancet Oncology

JF - The Lancet Oncology

IS - 9

ER -

Use of antineoplastic agents in patients with cancer who have HIV/AIDS

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this